(RTTNews) - Mainz Biomed N.V. (MYNZ), Thursday announced a collaboration with Quest Diagnostics Inc. (DGX) to commercialize the former's NextGen screening test for colorectal cancer, called ColoAlert ...
Mainz Biomed has announced a partnership with Quest Diagnostics to support the commercialisation of its NextGen colorectal cancer screening test, ColoAlert. The test leverages polymerase chain ...
With colon cancer rates rising, advocates hope a newly approved blood test screening can help more people catch it early. “If we find it early, we have a lot more options in treating it,” said Dr.
Colorectal cancer (CRC) is the third most common cancer globally, with more than 1.9 million new cases reported in 2020, according to World Cancer Research Fund. The US Preventive Services Task Force ...